The following discussion is an archived debate of the proposed deletion of the article below. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.

The result was no consensus‎. Daniel (talk) 02:10, 31 December 2023 (UTC)[reply]

Manish Doshi

[edit]
AfDs for this article:

[Hide this box] New to Articles for deletion (AfD)? Read these primers!

Manish Doshi (edit | talk | history | protect | delete | links | watch | logs | views) – (View log | edits since nomination)
(Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL)

Article fails WP:GNG, WP:BASIC and WP:BIO. Charlie (talk) 17:46, 2 December 2023 (UTC)[reply]

Relisted to generate a more thorough discussion and clearer consensus.
Please add new comments below this notice. Thanks, Eddie891 Talk Work 18:06, 9 December 2023 (UTC)[reply]

  1. He received a National Award from the Government of India through President Ram Nath Kovind and the Champions of Change Award from the Telangana state for his work in cardiovascular innovations and drug delivery devices.
  3. He is a pioneer in developing the world's first sirolimus-drug coated balloon named MagicTouch, which has earned him widespread recognition and accolades. The media, both nationally and internationally, has extensively discussed this.
  5. The product was granted the Breakthrough Device designation and IDE approvals from the USFDA for treating superficial femoral arteries (SFA).[1] Extensively studied globally in various clinical trials, such as the Eastbourne registry, Nanolute, and ongoing trials like Transform 1, Transform 2, Ginger, Titan, and Hybrid Bifurcation DEB.
  7. Dr. Martin Leon, founder of the Cardiovascular Research Foundation and leads the IDE trials, said that the "FDA approval for the MAGICAL-SV clinical trial using the MagicTouch sirolimus-covered balloon with nanolute technology is a significant milestone in their ongoing effort to find the best therapy for managing patients with small vessel coronary obstructive disease."[2]
  9. the company received a substantial $60 million funding from Kiran C Patel, a renowned cardiologist and businessman, specifically for conducting clinical studies on cardiac devices.[3]
  11. MagicTouch is currently the only globally approved sirolimus-coated balloon with CE certification and with extensive commercial usage in Europe, major markets of Asia and the Mid-Eastern markets. More than 100 thousand patients have been treated with MagicTouch SCB in these markets.[4]
  13. It is the most extensively studied sirolimus-coated balloon for peripheral artery disease (PAD) treatment and is the focus of ongoing clinical studies in the United Kingdom, Italy, and Brazil.[5][6]

so meets criterion 1 & 2 of ANYBIO.VikingsKhan (talk) 17:49, 13 December 2023 (UTC)[reply]

@Worldiswide: Wait, so you're saying that receiving a National Award from the Government of India, presented by former President Ram Nath Kovind, and being honored with the 'Champions of Change Award Telangana' by Telangana Governor are not noteworthy achievements? Seriously? Can you explain how you came to that conclusion? VikingsKhan (talk) 16:01, 14 December 2023 (UTC)[reply]

Relisted to generate a more thorough discussion and clearer consensus.
Please add new comments below this notice. Thanks, Daniel (talk) 20:54, 16 December 2023 (UTC)[reply]

Device might be notable, he likely isn't. Being FDA certified isn't notable, it's needed to sell medical items in the USA. The award could be notable, but there are no sources outside of press releases about the event. Oaktree b (talk) 21:28, 16 December 2023 (UTC)[reply]
Yes @Oaktree b:, the individual has received several noteworthy awards such as Champions of Change, a national award by the Government of India, an Honorary Doctorate, Marico Innovation Foundation's Innovation for India Award. These awards were given for his pioneering work in nanotechnology-based drug delivery for cardiovascular devices. Here are sources to verify these awards 1 2, 3. With these awards, the individual meets the first criterion of WP:ANYBIO (The person has received a well-known and significant award or honor, or has been nominated for such an award several times).
He is widely recognized for developing the world’s first Sirolimus Coated Balloon as well as a Sirolimus Eluting Stent, known as MagicTouch, used for the treatment of DM and AMI. MagicTouch is the only globally approved sirolimus-drug-coated balloon with CE certification, widely used in Europe, Asia, and the Middle East. It holds the exclusive Breakthrough Device designation from the USFDA. Moreover, Dr. Martin Leon, founder of the Cardiovascular Research Foundation and leads the IDE trials, said "FDA approval for the MAGICAL-SV clinical trial using the MagicTouch sirolimus-covered balloon with nanolute technology is a significant milestone in their ongoing effort to find the best therapy for managing patients with small vessel coronary obstructive disease."5. The company reportedly holds more than 100 patents for its technology and products globally and is the only company currently with the most clinically studied Sirolimus-coated balloon with long follow-up in Coronary and Peripheral. it received the National Technology Award from the Indian Government. An article in Outlook Business 6, provides detailed coverage of Dr. Doshi and MagicTouch. These achievements highlight the individual's notable contributions to the medical sector, meeting the WP:ANYBIO's second criterion (The person has made a widely recognized contribution that is part of the enduring historical record in a specific field). VikingsKhan (talk) 15:57, 18 December 2023 (UTC)[reply]
Again, the device is likely notable, he doesn't appear to be. The awards are fine, but we have little sourcing about them. The first one you've shared is fine, the second I can't open, the third is a press-release. Even above you continually mention how notable the device is. Oaktree b (talk) 16:15, 18 December 2023 (UTC)[reply]
@Oaktree b: The second link is an Indian-based website and may not be accessible in your country. However, any editors from India would be able to open it up. I have added an archived version of the same website here, and maybe you will be able to access it to verify the Champions of Change award that this person won. VikingsKhan (talk) 17:01, 18 December 2023 (UTC)[reply]

Relisted to generate a more thorough discussion and clearer consensus.
Relisting comment: Final relist.
Please add new comments below this notice. Thanks, Daniel (talk) 00:10, 24 December 2023 (UTC)[reply]

The above discussion is preserved as an archive of the debate. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.
More